Market news

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation range while the core franchise shrinks, and that the market underestimates how hard the idiopathic pulmonary fibrosis (IPF) launch will […]

Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization. At the same time, United Therapeutics is pushing ahead with long-horizon xenotransplantation efforts, including a xenokidney registration trial that management aims to...

United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.

United Therapeutics (UTHR) moved into focus after Goldman Sachs started coverage with a Sell rating, sending the stock down 4%, a meaningful single session move for a relatively steady biotech stock. Goldman’s call lands after a choppy stretch for United Therapeutics, with the share price down 7.76% over 30 days and 12.75% over 90 days, even though the 1-year total shareholder return of 9.89% and 3-year total shareholder return of 110.50% point to longer term momentum that appears...

United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share rep

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of the stock with a Sell rating.

United Therapeutics (UTHR) stock and Sagimet Biosciences (SGMT) stock slip as Goldman Sachs issued Sell ratings on the companies. Read more here.

United Therapeutics gets a reiterated “buy” rating on upcoming PDUFA dates and other catalysts that could drive future growth. Click here to read more on UTHR.

Martine A Rothblatt, Director, Chairperson & CEO, on September 17, 2026, sold 9,500 shares in United

Martine A Rothblatt, Director, Chairperson & CEO, on September 14, 2026, sold 9,500 shares in United

United Therapeutics Corporation (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion authorization to an accelerated share repurchase with Citibank, N.A. on September 8. Earlier transactions included $1.5 billion of accelerated repurchases and $22.4 million of open-market purchases. The upfront payment was scheduled for around September 10, with initial delivery representing approximately 75% of […]

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers.

United Therapeutics (UTHR) said Tuesday that it will use the remaining $477.6 million of its $2 bill

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 08, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase the company’s common stock, for approximately $477.6 million

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

Martine A Rothblatt, Director, Chairperson & CEO, on September 01, 2026, sold 9,500 shares in United

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 02, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication.

United Therapeutics (UTHR) said Wednesday the US Food and Drug Administration has accepted its suppl

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 01, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat sessions at four upcoming investor conferences.

United Therapeutics (UTHR) presents Phase 3 data on ralinepag and inhaled treprostinil at EU congresses, as FDA reviews PAH/IPF filings—read the update.

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

United Therapeutics (UTHR) is back in focus after the FDA accepted its New Drug Application for ralinepag, an investigational once daily oral prostacyclin for pulmonary arterial hypertension, with a target action date set for June 24, 2027. See our latest analysis for United Therapeutics. The ralinepag filing comes after a strong run for United Therapeutics, with the stock delivering a 67.95% total shareholder return over the past year even as the 90 day share price return declined 11.33%...

United Therapeutics Corporation (NASDAQ:UTHR) has moved ralinepag into formal FDA review after the regulator accepted its New Drug Application for the investigational pulmonary arterial hypertension treatment. The FDA filing acceptance establishes a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, giving investors a defined regulatory catalyst following positive Phase 3 results.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 24, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 17, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients.

United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized progress in the company’s clinical programs, particularly the ADVANCE OUTCOMES study for ralinepag and the TETON-1 trial for Tyvaso in pulmonary fibrosis. President Michael Benkowitz noted that although revenue was flat sequentially, o